B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) Ltd on Wednesday, setting a price target of $70, which is approximately 20.23% above the present share price of $58.22.
Mamtani expects Arcturus Therapeutics Ltd to post earnings per share (EPS) of -$0.67 for the third quarter of 2020.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Arcturus Therapeutics, with an average price target of $56.25.
The analysts price targets range from a high of $72 to a low of $31.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $2.65 million and a net profit of -$9.46 million. The company's market cap is $1.18 billion.
According to TipRanks.com, B.Riley FBR analyst Mayank Mamtani is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 17.5% and a 50.26% success rate.
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.